Previously submitted to: JMIR Research Protocols (no longer under consideration since Aug 06, 2026)
Date Submitted: Jun 22, 2026
Open Peer Review Period: Jun 23, 2026 - Jul 14, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Vitamin E for Metabolic Dysfunction-Associated Steatohepatitis: Protocol for A Meta-Analysis Based on Randomized Controlled Trials
ABSTRACT
Background:
Background:
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited approved pharmacotherapies. Vitamin E, an antioxidant, has shown potential but evidence on its efficacy and safety remains inconsistent across patient subgroups.
Objective:
This protocol outlines a systematic review and meta-analysis of randomized controlled trials (RCTs) that will evaluate the effects of Vitamin E on liver function and safety outcomes in MASH, aiming to provide evidence for clinical patient care, nutritional guidance, and health education in liver disease management.
Methods:
Methods:
This protocol will follow the PRISMA-P guidelines and has been registered with PROSPERO. PubMed, Embase, Cochrane Library, and Web of Science will be searched from inception without language restrictions. Eligible RCTs will enroll adults with MASH, comparing Vitamin E (any dose) with placebo or active comparators administered equally across groups. Primary outcomes will be changes in alanine aminotransferase (ALT) and the incidence of adverse events and serious adverse events. Two reviewers will independently perform study selection, data extraction, and risk of bias assessment using RoB 2. Random-effects meta-analyses will be conducted, with subgroup analyses by dosage, diabetes status, fibrosis stage, and treatment duration. GRADE will be used to assess evidence certainty.
Results:
Meta‑analyses will be conducted using RevMan 5.4 and R with the meta package. For continuous outcomes such as changes in ALT, mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals (CI) will be calculated. For dichotomous safety outcomes, risk ratios (RR) with 95% CIs will be used.
Conclusions:
his protocol outlines a planned systematic review and meta-analysis that will provide theoretical basis and practical reference for the optimization of clinical nursing work. To our knowledge, this will be one of the first meta-analyses to focus concurrently on liver function biomarkers as efficacy outcomes and on a broad spectrum of adverse events as primary safety endpoints, specifically within the framework of the updated MASLD nomenclature. By restricting inclusion to RCTs and employing rigorous methodological tools such as RoB 2 and the GRADE framework, this study will aim to provide a high-quality evidence synthesis that addresses key uncertainties remaining in the field. Clinical Trial: PROSPERO registration number: CRD420261348120.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.